by [email protected] | Dec 20, 2022 | Blog
Our Vice President, Real-World Evidence (RWE) shares her perspective about HEOR, RWD, evidence generation, and more. (First in a 2-part series) What is the current landscape for pharmaceutical and biotechnology products? It is an exciting time. I’ve spent 30 years in...
by [email protected] | Oct 5, 2022 | Blog
Lowering prescription drug costs and health care costs are among the goals of the Inflation Reduction Act. While changes will not take effect until 2025, what can the biopharmaceutical industry expect? Keshia Maughn, Senior Principal, Strategic Advisory Services at...
by [email protected] | Aug 30, 2022 | Blog
More from our VP of RWE, Maxine Fisher, PhD What is the team’s approach with RWD to generate evidence and demonstrate value? One thing that is very motivating about working at STATinMED is our collaborative and consultative approach to generating evidence. RWD...
by [email protected] | Jul 26, 2022 | Blog
Want to learn more about STATinMED and the power of RWD Insights? Here we share some common questions, with answers about our data source and approach. Is your data source HIPAA-compliant? Yes, our data source is de-identified, tokenized, and meets the...
by [email protected] | Mar 24, 2022 | Blog
Study Purpose and Population Epidemiology of rare diseases is important for clinicians to consider, as prevalence and incidence inform the healthcare community about likelihood of disease within an at-risk population. Studies in epidemiology also help to support...
